Delayed-Onset Vitiligo in Metastatic HR+/HER2- Breast Cancer During Long-Term Ribociclib Therapy

Division

Gulf Coast

Hospital

HCA Houston Healthcare Clear Lake

Document Type

Case Report

Publication Date

12-23-2025

Keywords

breast cancer, cyclin-dependent kinase 4/6 inhibitors, ribociclib, vitiligo

Disciplines

Internal Medicine | Medicine and Health Sciences | Neoplasms | Skin and Connective Tissue Diseases

Abstract

UNLABELLED: Vitiligo is a rare cutaneous adverse event associated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. We report a 56-year-old woman with de novo metastatic HR

LEARNING POINTS: This case highlights that cutaneous autoimmune-like toxicities, while concerning in appearance, do not necessarily warrant discontinuation of an effective anticancer drug if they are mild.Oncologists and dermatologists should be aware of CDK4/6 inhibitor-associated vitiligo, even late in the treatment timeline, and approach it with a collaborative management strategy.Moving forward, further research into the immunological or apoptotic mechanisms of this toxicity may shed light on why it occurs and how best to treat it.

Publisher or Conference

European Journal of Case Reports in Internal Medicine

Link to Full Text

Share

COinS